{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:05:27Z","timestamp":1784189127102,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40273-026-01619-y","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:29:46Z","timestamp":1778678986000},"page":"985-994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Alternative Outcome Measures in Cost-Effectiveness Analysis: Three Applications Within Oncology"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-517X","authenticated-orcid":false,"given":"Brian","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Telford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Ambavane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugam","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Jaime","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"1619_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1287\/opre.18.6.1021","volume":"18","author":"S Fanshel","year":"1970","unstructured":"Fanshel S, Bush JW. A health-status index and its application to health-services outcomes. Oper Res. 1970;18:1021\u201366.","journal-title":"Oper Res"},{"key":"1619_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/00005650-196801000-00005","volume":"6","author":"HE Klarman","year":"1968","unstructured":"Klarman HE, Francis JO, Rosenthal GD. Cost effectiveness analysis applied to the treatment of chronic renal disease. Med Care. 1968;6:48\u201354.","journal-title":"Med Care"},{"key":"1619_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1212439","volume":"12","author":"S Eckermann","year":"2024","unstructured":"Eckermann S. Aligning opportunity cost and net benefit criteria: the health shadow price. Front Public Health. 2024;12:1212439. https:\/\/doi.org\/10.3389\/fpubh.2024.1212439.","journal-title":"Front Public Health"},{"key":"1619_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1287\/opre.28.1.206","volume":"28","author":"JS Pliskin","year":"1980","unstructured":"Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Operations Res. 1980;28:206\u201324.","journal-title":"Operations Res"},{"key":"1619_CR5","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/j.1524-4733.2009.00516.x","volume":"12","author":"E Nord","year":"2009","unstructured":"Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health. 2009;12:S10-15.","journal-title":"Value Health"},{"key":"1619_CR6","doi-asserted-by":"crossref","unstructured":"Phelps CE, Lakdawalla DN. Valuing health: the generalized and risk-adjusted cost-eff ectiveness (GRACE) model. Oxford: Oxford University Press; 2024. p. 1\u2013329.","DOI":"10.1093\/oso\/9780197686287.003.0001"},{"key":"1619_CR7","volume-title":"Cost-effectiveness in health and medicine","author":"PJ Neumann","year":"2021","unstructured":"Neumann PJ, Cohen JT, Kim DD. Cost-effectiveness in health and medicine. 2nd ed. Oxford: Oxford University Press; 2021.","edition":"2nd ed"},{"key":"1619_CR8","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511609145","volume-title":"Cost-value analysis in health care: making sense out of QALYs","author":"E Nord","year":"1999","unstructured":"Nord E. Cost-value analysis in health care: making sense out of QALYs. Cambridge: Cambridge University Press; 1999."},{"issue":"6","key":"1619_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jval.2024.02.013","volume":"27","author":"MW Njoroge","year":"2024","unstructured":"Njoroge MW. Understanding the National Institute for Health and Care Excellence severity premium: exploring its implementation and the implications for decision making and patient access. Value Health. 2024;27(6):730\u20136.","journal-title":"Value Health"},{"key":"1619_CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"ISPOR Special Task Force on Value Assessment","year":"2018","unstructured":"ISPOR Special Task Force on Value Assessment. PHP286 - Responses of ISPOR members to the recommendations of the Special Task Force on US value assessment frameworks. Value Health. 2018;21:131\u20139.","journal-title":"Value Health"},{"issue":"1","key":"1619_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/(SICI)1099-1050(199902)8:1<25::AID-HEC398>3.0.CO;2-H","volume":"8","author":"E Nord","year":"1999","unstructured":"Nord E, Pinto JL, Richardson J, Menzel P, Ubel P. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ. 1999;8(1):25\u201339.","journal-title":"Health Econ"},{"issue":"1","key":"1619_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jval.2019.10.014","volume":"23","author":"A Basu","year":"2020","unstructured":"Basu A, Carlson J, Veenstra D. Health years in total: a new health objective function for cost-effectiveness analysis. Value Health. 2020;23(1):96\u2013103.","journal-title":"Value Health"},{"issue":"10","key":"1619_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40273-023-01302-6","volume":"41","author":"JD Campbell","year":"2023","unstructured":"Campbell JD, Whittington MD, Pearson SD. An alternative measure of health for value assessment: the equal value life-year. Pharmacoeconomics. 2023;41(10):1175\u201382. https:\/\/doi.org\/10.1007\/s40273-023-01302-6.","journal-title":"Pharmacoeconomics"},{"key":"1619_CR14","unstructured":"Canadian Cancer Society. Survival statistics for chronic myeloid leukemia. 2022. Available from: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/chronic-myeloid-leukemia-cml\/prognosis-and-survival\/survival-statistics. [Accessed 13 Jan 2025]."},{"key":"1619_CR15","unstructured":"Robertson S. Renal cell carcinoma survival rate. 2023. Available from: https:\/\/www.news-medical.net\/health\/Renal-Cell-Carcinoma-Survival-Rate.aspx. [Accessed 13 Jan 2025]."},{"key":"1619_CR16","volume-title":"Non-small cell lung cancer survival rates, by stage","author":"American Cancer Society","year":"2016","unstructured":"American Cancer Society. Non-small cell lung cancer survival rates, by stage. Atlanta (GA): American Cancer Society, Inc.; 2016."},{"issue":"1","key":"1619_CR17","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0163","volume":"14","author":"N Atreja","year":"2025","unstructured":"Atreja N, Johannesen K, Subash R, Bektur C, Hagan M, Hines DM, et al. US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total. J Comp Eff Res. 2025;14(1):e240163.","journal-title":"J Comp Eff Res"},{"issue":"6","key":"1619_CR18","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jval.2024.03.644","volume":"27","author":"FE Moustaid","year":"2024","unstructured":"Moustaid FE, Rosettie K. EE346 expanding cost-effectiveness analysis to demonstrate population-level treatment impact on patients and society. Value Health. 2024;27(6):S121.","journal-title":"Value Health"},{"issue":"2","key":"1619_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/14737167.2023.2283584","volume":"24","author":"MJ DiStefano","year":"2024","unstructured":"DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024;24(2):171\u201380.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"12","key":"1619_CR20","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jval.2024.10.406","volume":"27","author":"M Zemojdzin","year":"2024","unstructured":"Zemojdzin M, Pochopien M, Dziedzic J, Clay E, Aballea S, Toumi M. EE122 from quality-adjusted life years (QALY) to equal value of life years (evLY): a study on non-alcoholic steatohepatitis (NASH) subpopulations. Value Health. 2024;27(12):S78.","journal-title":"Value Health"},{"issue":"1","key":"1619_CR21","first-page":"26","volume":"7","author":"K O\u2019Day","year":"2021","unstructured":"O\u2019Day K, Mezzio DJ. Demystifying ICER\u2019s equal value of life years gained metric. Value Outcomes Spotlight. 2021;7(1):26\u20138.","journal-title":"Value Outcomes Spotlight"},{"issue":"6","key":"1619_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-024-01385-9","volume":"42","author":"WL Herring","year":"2024","unstructured":"Herring WL, Gallagher ME, Shah N, Morse K, Mladsi D, Dong OM, et al. Cost-effectiveness of lovotibeglogene autotemcel (Lovo-Cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024;42(6):693\u2013714.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1619_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jval.2023.11.009","volume":"27","author":"M Paulden","year":"2024","unstructured":"Paulden M, Sampson C, O\u2019Mahony JF, Spackman E, McCabe C, Round J, et al. Logical inconsistencies in the health years in total and equal value of life-years gained. Value Health. 2024;27(3):356\u201366.","journal-title":"Value Health"},{"key":"1619_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40258-022-00730-3","volume":"20","author":"C Sampson","year":"2022","unstructured":"Sampson C, Zamora B, Watson S, et al. Supply-side cost-effectiveness thresholds: questions for evidence-based policy. Appl Health Econ Health Policy. 2022;20:651\u201367.","journal-title":"Appl Health Econ Health Policy"},{"key":"1619_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.2023.1792","volume":"329","author":"PJ Neumann","year":"2023","unstructured":"Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990-2021. JAMA. 2023;329:1312\u20134. https:\/\/doi.org\/10.1001\/jama.2023.1792.","journal-title":"JAMA"},{"key":"1619_CR26","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the NICE cost effectiveness threshold. CHE Research Paper 81, November 2013. Available from: http:\/\/www.york.ac.uk\/che\/research\/teehta\/thresholds\/. [Accessed 24 Apr 2026]."},{"key":"1619_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40273-021-01087-6","volume":"40","author":"LC Edney","year":"2022","unstructured":"Edney LC. Empirical estimates of the marginal cost of health produced by a healthcare system: methodological considerations from country-level estimates. Pharmacoeconomics. 2022;40:31\u201343.","journal-title":"Pharmacoeconomics"},{"key":"1619_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","volume":"174","author":"DJ Vanness","year":"2021","unstructured":"Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-effectiveness analysis in the United States. Ann Intern Med. 2021;174:25\u201332.","journal-title":"Ann Intern Med"},{"key":"1619_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40273-024-01441-4","volume":"43","author":"L Vallejo-Torres","year":"2025","unstructured":"Vallejo-Torres L. Estimating the incremental cost per QALY produced by the Spanish NHS: a fixed-effect econometric approach. Pharmacoeconomics. 2025;43:109\u201322.","journal-title":"Pharmacoeconomics"},{"key":"1619_CR30","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11:e833\u201342.","journal-title":"Lancet Glob Health"},{"key":"1619_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40258-021-00707-8","volume":"20","author":"L Vallejo-Torres","year":"2022","unstructured":"Vallejo-Torres L, Garcia-Lorenzo B, Edney LC, et al. Are estimates of the health opportunity cost being used to draw conclusions in published cost-effectiveness analyses? A scoping review in four countries. Appl Health Econ Health Policy. 2022;20:337\u201349.","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"1619_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.36469\/001c.147469","volume":"12","author":"M Enami","year":"2025","unstructured":"Enami M, Yuasa A, Ikeda S. Quantifying disease severity in health technology assessment in Japan: a retrospective analysis using quality-adjusted life-year shortfalls. J Health Econ Outcomes Res. 2025;12(2):229\u201336. https:\/\/doi.org\/10.36469\/001c.147469.","journal-title":"J Health Econ Outcomes Res"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01619-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:20:49Z","timestamp":1784186449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01619-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01619-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Brian Reddy and Claire Telford are employees of Pfizer. Sugam Mahajan, Apoorva Ambavane, and Jaime Caro are employees of ThermoFisher, which received financial support from Pfizer in connection with the study and the development of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The article has no associated relevant data and as such the data will not be deposited.","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design, data acquisition, analysis, and interpretation, and drafting and revising of the manuscript.","order":6,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}